Αποτελέσματα Αναζήτησης
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal, multi-center, observational study. The overall goal of ADNI is to validate biomarkers for Alzheimer’s disease (AD) clinical trials.
- About
About - ADNI | Alzheimer's Disease Neuroimaging Initiative
- News & Publications
News & Publications - ADNI | Alzheimer's Disease...
- HELP / FAQ
HELP / FAQ - ADNI | Alzheimer's Disease Neuroimaging...
- About
30 Ιουν 2011 · Clinical data from the ADNI 1, ADNI GO and ADNI 2 phases of the project are now available in the the ADNI Repository (IDA). Once logged in, you may peruse and download assessment, medical history, biospecimen and other data from the DOWNLOAD | Study Data menu. See INSTRUCTIONS for more information.
28 Ιαν 2020 · A large set of preprocessed AD Neuroimaging Initiative (ADNI) data was analyzed with 3C.
This paper reviews the current status of the Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project.
22 Ιουλ 2015 · ! 2 PROTOCOL SYNOPSIS Title Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2) Primary Objective The major goals of ADNI2 are to: 1. Determine the relationships among clinical, imaging, genetic, and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s Disease (AD), as the pathology evolves from normal
12 Σεπ 2023 · The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies.
11 Σεπ 2024 · In addition to informing the design of clinical trials, ADNI data have been used extensively for observational research in normal brain aging and dementia to examine correlations between MRI, clinical, genetic, positron emission tomography (PET), and biofluid measures.
